Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Top Page
Shin Nippon Biomedical Laboratories, Ltd.
(2395)
Select Model
Select Model
Rating:74Outperform
Price Target:
¥1,630.00
▲(0.49% Upside)
Action:UpgradedDate:11/30/25
Shin Nippon Biomedical Laboratories has a strong technical outlook with bullish momentum, which is the most significant factor driving the score. Financial performance is solid but tempered by concerns over declining margins and rising debt. Valuation is reasonable, but not compelling enough to significantly boost the score.
Positive Factors
Contracted CRO business model
Shin Nippon’s core model is fee-based CRO work across nonclinical, clinical and laboratory-animal services, with revenue recognized as studies are performed. Contracted project work and diversified service lines support predictable, repeatable revenue streams and durable client relationships over quarters.
Negative Factors
Rising leverage
An increasing debt-to-equity trend raises financial risk and interest burden, limiting strategic flexibility. Higher leverage reduces cushion against project delays or client payment variability and amplifies downside in slower demand periods, constraining capacity to invest or absorb shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Contracted CRO business model
Shin Nippon’s core model is fee-based CRO work across nonclinical, clinical and laboratory-animal services, with revenue recognized as studies are performed. Contracted project work and diversified service lines support predictable, repeatable revenue streams and durable client relationships over quarters.
Read all positive factors
Shin Nippon Biomedical Laboratories, Ltd. (2395) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥61.62B
Dividend Yield2.79%
Average Volume (3M)231.41K
Price to Earnings (P/E)14.4
Beta (1Y)0.98
Revenue Growth28.06%
EPS Growth19.48%
CountryJP
Employees1,457
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)1.49
Price to Sales (P/S)1.84
P/FCF Ratio-15.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,745.00Price Target Upside69.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shin Nippon Biomedical Laboratories, Ltd. Business Overview & Revenue Model
Company Description
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; g...
How the Company Makes Money
The company primarily makes money by selling outsourced R&D services to customers (typically pharmaceutical and biotech companies) under contract arrangements. Key revenue streams include: (1) Nonclinical (preclinical) services: fees earned for co...
Shin Nippon Biomedical Laboratories, Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.34B | 32.41B | 26.45B | 25.09B | 17.75B | 15.11B |
| Gross Profit | 16.62B | 16.57B | 14.28B | 13.05B | 9.69B | 7.55B |
| EBITDA | 8.86B | 8.83B | 8.98B | 9.49B | 9.49B | 5.55B |
| Net Income | 5.06B | 4.92B | 5.53B | 6.06B | 7.13B | 3.66B |
Balance Sheet | ||||||
| Total Assets | 89.07B | 92.42B | 76.30B | 58.31B | 39.38B | 37.61B |
| Cash, Cash Equivalents and Short-Term Investments | 11.57B | 12.03B | 10.61B | 10.53B | 7.00B | 7.29B |
| Total Debt | 36.58B | 34.61B | 26.33B | 18.93B | 9.28B | 12.86B |
| Total Liabilities | 53.17B | 52.33B | 42.14B | 31.95B | 19.66B | 21.78B |
| Stockholders Equity | 35.51B | 40.02B | 34.11B | 26.21B | 19.56B | 15.73B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -3.82B | -6.50B | -951.70M | 4.34B | 3.63B |
| Operating Cash Flow | 0.00 | 7.04B | 2.11B | 4.00B | 5.95B | 4.75B |
| Investing Cash Flow | 0.00 | -11.69B | -6.91B | -5.93B | -4.27B | -268.66M |
| Financing Cash Flow | 0.00 | 5.91B | 5.32B | 6.27B | -4.91B | -2.47B |
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis
Negative
1622.00
Price Trends
1620.42
Negative
1662.04
Negative
1587.72
Negative
Market Momentum
-46.38
Positive
35.51
Neutral
7.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2395, the sentiment is Negative. The current price of 1622 is above the 20-day moving average (MA) of 1563.70, above the 50-day MA of 1620.42, and above the 200-day MA of 1587.72, indicating a bearish trend. The MACD of -46.38 indicates Positive momentum. The RSI at 35.51 is Neutral, neither overbought nor oversold. The STOCH value of 7.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2395.
Shin Nippon Biomedical Laboratories, Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥154.45B | 15.47 | 5.94% | 3.34% | 5.90% | 16.30% | |
74 Outperform | ¥61.62B | 14.39 | ― | 2.79% | 28.06% | 19.48% | |
68 Neutral | ¥97.03B | 26.70 | ― | 2.31% | 4.36% | 79.43% | |
52 Neutral | ¥6.19B | -2.65 | ― | 5.44% | -15.42% | -879.08% | |
52 Neutral | ¥138.12B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,480.00
12.03
0.82%
JP:4694
BML
4,130.00
1,162.69
39.18%
JP:2183
Linical Co., Ltd.
274.00
-50.81
-15.64%
JP:4549
Eiken Chemical Co., Ltd.
2,943.00
647.24
28.19%
JP:4974
Takara Bio Inc.
1,147.00
311.71
37.32%
Shin Nippon Biomedical Laboratories, Ltd. Corporate Events
SNBL Releases Q3 FY2026 Results Briefing and Business Update
Feb 6, 2026
Shin Nippon Biomedical Laboratories has released presentation materials for its consolidated financial results briefing for the third quarter of the fiscal year ending March 31, 2026. The briefing outlines the company’s Q3 performance and fu...
SNBL Cuts Full-Year Revenue and Operating Profit Outlook but Nudges Net Income Forecast Higher
Feb 6, 2026
Shin Nippon Biomedical Laboratories has revised its full-year consolidated forecast for the fiscal year ending March 31, 2026, lowering projected revenue and operating profit but slightly increasing profit attributable to owners of the parent. Rev...
Shin Nippon Biomedical Laboratories Cuts Earnings Outlook Amid Profit Decline but Maintains Dividend Plan
Feb 6, 2026
Shin Nippon Biomedical Laboratories reported consolidated results for the nine months ended December 31, 2025, showing revenue down 4.7% year-on-year to ¥21.2 billion and steep declines in operating profit (down 45.7%), ordinary profit (down ...
SNBL Warns of Added Costs as U.S. Migraine Drug Unit Talks Continue
Jan 5, 2026
SNBL has announced an update on its U.S. subsidiary Satsuma Pharmaceuticals, which is continuing negotiations for a partnering arrangement for Atzumi™, an intranasal migraine treatment, with discussions still in progress. The company’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.